MDACC Study No:GOG 0274 ( NCT No: NCT01414608)
Title:A Phase III Trial of Adjuvant Chemotherapy Following Chemoradiation as Primary Treatment for Locally Advanced Cervical Cancer Compared to Chemoradiation Alone: THE OUTBACK TRIAL (ANZGOG 0902 /GOG 0274 / RTOG 1174)
Principal Investigator:Lois M. Ramondetta
Treatment Agent:Chemoradiotherapy
Study Status:Open
Study Description:The goal of this clinical research study is to learn if giving carboplatin and
paclitaxel after standard therapy for locally advanced cervical cancer can help
to control the disease for a longer time than the standard therapy alone. The
standard therapy is radiation therapy combined with the chemotherapy drug
cisplatin (chemo-radiation). The safety of the combination treatment will also
be studied.

Cisplatin is designed to poison the cancer cells, which may cause them to die.

Carboplatin and paclitaxel are designed to block cancer cells from dividing,
which may cause them to die.

Radiation therapy is designed to kill cancer cells by damaging their DNA
(genetic material).
Hide details for General InformationGeneral Information

Disease Group:Cervix
Phase of Study:Phase III
Treatment Agents:Chemoradiotherapy
Treatment Location:Both at MDACC & and Other Sites
Estimated Length of Stay in Houston:
Supported By:GOG
Return Visit:
Home Care:

Hide details for Study Contact InformationStudy Contact Information

Physician Name:Lois M. Ramondetta
Dept:Gynecologic Oncology
For Clinical Trial Enrollment:713-745-0307
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)

Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults